Key result
Treatment with Etoposide/Carboplatin instead of Etoposide/Cisplatin in a young male with germ cell tumor and Takotsubo cardiomyopathy resulted in no relapse after 4.6 years of follow-up.
Case Report (n=1)
Etoposide/Carboplatin may be a safe and effective alternative to Etoposide/Cisplatin in patients with germ cell tumors who develop Takotsubo cardiomyopathy, avoiding further myocardial injury.
Germ cell tumors (GCT) are uncommon malignancies in adult males and comprise less than 1% of male cancers. Due to highly curative nature and productive life years gained after treatment; reduction of chemotherapy related toxicities becomes vital. Cisplatin is the backbone of GCT chemotherapy, & is related to myocardial injury, thromboembolism & vasculitis. Though it should not be replaced with Carboplatin, however in certain circumstances, its use maybe unsafe; especially in cases when patient have prior myocardial infarction. We report a case of Takotsubo cardiomyopathy (TCM)secondary to GCT diagnosis in a young male. This patient presented with symptoms of myocardial infarction however, coronary angiography was normal and a diagnosis of TCM was made. Though, it is rare but a unique challenge, as whether Cisplatin use would be safe in this particular scenario? On one hand patient had stress related myocardial injury while he was also at risk of further Cisplatin induced complications. There are no clear cut guidelines, so after informed consent his treatment regimen was modified to EC (Etoposide/Carboplatin) instead of EP (Etoposide/Cisplatin). Patient has completed 4.6 years of follow-up without any evidence of relapse. We suggest informed decisions and to weigh the pros and cons of using an inferior regimen, in order to achieve same long term prognosis while preventing any acute complications, in younger patients with curable cancers.
No takes yet. Share an insight, caveat, or question.
Hannan et al. (2018) conducted a case report in Germ cell tumor and Takotsubo Cardiomyopathy (n=1). EC (Etoposide/Carboplatin) vs. EP (Etoposide/Cisplatin) was evaluated on relapse. Treatment with Etoposide/Carboplatin instead of Etoposide/Cisplatin in a young male with germ cell tumor and Takotsubo cardiomyopathy resulted in no relapse after 4.6 years of follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: